Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
about
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical TrialsAssessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinasesSEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domainsA selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposureClipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).Inhibitors of cyclin-dependent kinases as cancer therapeutics.Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19.CDK8 Kinase Activity Promotes Glycolysis.WNT signalling in prostate cancer.Transcriptional kinases: Less is more (or less).Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).Novel molecular insights and new therapeutic strategies in osteosarcoma
P2860
Q27703668-F3AF0068-35C8-43E3-A5CA-A6C00EB16EA4Q28078703-FEEC306A-EF89-483A-8E23-1D26AF6C53DDQ28817622-07DCA2A2-4756-4BFC-BCE9-633EC7044791Q33779684-BB0B9C68-9BD3-4716-B426-6E912654A944Q36367502-FBEFC7FC-998C-4993-9A54-6EE4C37C31C3Q36454906-C90827A5-B53D-4A5D-9455-F33714D90F44Q38775522-1928BBBF-F742-444B-B134-5E4DBFA3AA0AQ38949247-80B374CC-DEC9-4901-9A0C-B3CBFE7E0792Q39125016-9EA92033-1655-41DB-8A80-F2FA6EA93163Q40075759-E3E09A06-6B98-4064-9738-371A36774E01Q42695709-3EC5BB87-DD9B-4F54-9339-7174458C3389Q47129821-3AF619C1-49A8-4DE3-8BC1-D185C023AD87Q47818549-CB3B6A8A-7252-4044-9BE1-EF35EE60FB3AQ55034077-A813EF08-C189-4DC9-B093-4F3473FF01EEQ55509442-E8CBE333-5C4B-4476-92DB-9B2E0AF1367DQ57814118-34BC04A8-09E4-4CD2-86D8-2D6F8215BB4F
P2860
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@ast
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@en
type
label
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@ast
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@en
prefLabel
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@ast
Discovery of potent, orally bi ...... m a cell-based pathway screen.
@en
P2093
P2860
P50
P356
P1476
Discovery of potent, orally bi ...... om a cell-based pathway screen
@en
P2093
Alan T Henley
Alexis De Haven Brandon
Aurélie Mallinger
Birgitta Leuthner
Bozena Wood
Ching Thai
Christina Esdar
Dennis Waalboer
Dirk Wienke
Elizabeth Smith
P2860
P304
P356
10.1021/JM501436M
P407
P577
2015-02-13T00:00:00Z